» Articles » PMID: 17177846

5-FdUrd-araC Heterodinucleoside Re-establishes Sensitivity in 5-FdUrd- and AraC-resistant MCF-7 Breast Cancer Cells Overexpressing ErbB2

Abstract

ErbB2 overexpressing breast tumors have a poor prognosis and a high risk to develop chemoresistance to therapeutic treatment. "Chemoresistance" is a response of cells to toxic stress, and, although it is a common phenomenon, it is still poorly defined. However, a detailed understanding is required to target desensitized pathways and mechanisms for successful reactivation as part of a tailored therapy. To gain insight, which malfunctions contribute to chemoresistance, two mechanisms relevant for tissue homeostasis, the regulation of the cell cycle and of apoptosis, were investigated. Maternal MCF-7- and ErbB2-overexpressing MCF-7(erbB2) breast cancer cells were long term pretreated with 2'-deoxy-5-fluorodeoxyuridine (5-FdUrd) or 1-beta-d-arabinofuranosylcytosine (AraC) and the acquisition of drug-insensitivity was analyzed. A phosphate-conjugated heterodinucleoside consisting of one 5-FdUrd- and one AraC-moiety (5-fluoro-2'-desoxyuridylyl-(3'-->5')-Arabinocytidine) was utilized as a tool to assess the type of acquired resistances. ErbB2-overexpression disrupted proper cell cycle regulation and furthermore facilitated the development of an apoptosis-refractory phenotype upon exposure to 5-FdUrd. Experiments with dimer 5-FdUrd-araC in ErbB2-overexpressing MCF-7(erbB2) cells, and also with nucleoside 5-FdUrd in maternal MCF-7 cells, evidenced that the phenotypes of resistance to cell cycle inhibition and to apoptosis induction were differently affected. The expression profile of cyclin D1 (but not that of p53, p21, or p27) correlated with the proliferative phenotypes and nuclear accumulation of apoptosis inducing factor (but not activation of caspase 7) with apoptotic phenotypes. Dimer 5-FdUrd-araC overrode acquired chemoresistances, whereas combined application of 5-FdUrd and AraC exhibited significantly less activity. Dimer 5-FdUrd-araC remained active in MCF-7 clones most likely by circumventing the prerequisite of first-step phosphorylation. The acquisition of chemoresistance encompassed the affection of apoptosis- and cell-cycle regulation to, respectively, different extents. Thus, drug-induced cell cycle arrest and apoptosis induction are independent of each other.

Citing Articles

Pharmacokinetics, Molecular Docking and Molecular Dynamics Simulation Studies of Nucleoside Analogs for Drug Discovery- A Mini Review.

Kawsar S, Munia N, Saha S, Ozeki Y Mini Rev Med Chem. 2023; 24(11):1070-1088.

PMID: 37957918 DOI: 10.2174/0113895575258033231024073521.


antimicrobial, physicochemical, pharmacokinetics and molecular docking studies of benzoyl uridine esters against SARS-CoV-2 main protease.

Matin M, Uzzaman M, Chowdhury S, Bhuiyan M J Biomol Struct Dyn. 2020; 40(8):3668-3680.

PMID: 33297848 PMC: 7738211. DOI: 10.1080/07391102.2020.1850358.


Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.

Giessrigl B, Schmidt W, Kalipciyan M, Jeitler M, Bilban M, Gollinger M Br J Cancer. 2013; 109(10):2751-62.

PMID: 24169358 PMC: 3833203. DOI: 10.1038/bjc.2013.583.


Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Jordheim L, Durantel D, Zoulim F, Dumontet C Nat Rev Drug Discov. 2013; 12(6):447-64.

PMID: 23722347 DOI: 10.1038/nrd4010.


Fractionation of an Extract of Pluchea odorata Separates a Property Indicative for the Induction of Cell Plasticity from One That Inhibits a Neoplastic Phenotype.

Seelinger M, Popescu R, Seephonkai P, Singhuber J, Giessrigl B, Unger C Evid Based Complement Alternat Med. 2012; 2012:701927.

PMID: 22474515 PMC: 3312255. DOI: 10.1155/2012/701927.